Balyasny Asset Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-505,957
| Closed | -$64.9M | – | 2935 |
|
|
2025
Q2 | $64.9M | Buy |
505,957
+445,675
| +739% | +$46.3M | 0.1% | 245 |
|
|
2025
Q1 | $5.34M | Sell |
60,282
-42,204
| -41% | -$4.12M | 0.01% | 1217 |
|
|
2024
Q4 | $8.94M | Buy |
102,486
+78,736
| +332% | +$7.21M | 0.01% | 1014 |
|
|
2024
Q3 | $2.2M | Buy |
+23,750
| New | +$2.36M | ﹤0.01% | 1629 |
|
|
2024
Q1 | – | Sell |
-5,207
| Closed | -$480K | – | 2634 |
|
|
2023
Q4 | $480K | Buy |
+5,207
| New | +$337K | ﹤0.01% | 1965 |
|
|
2023
Q1 | – | Sell |
-941
| Closed | -$41.2K | – | 2675 |
|
|
2022
Q4 | $41.2K | Buy |
+941
| New | +$45.1K | ﹤0.01% | 2372 |
|
|
2022
Q1 | – | Sell |
-42,053
| Closed | -$4.5M | – | 2487 |
|
|
2021
Q4 | $4.5M | Buy |
42,053
+14,531
| +53% | +$1.52M | 0.02% | 879 |
|
|
2021
Q3 | $2.83M | Sell |
27,522
-87,637
| -76% | -$8.16M | 0.01% | 1018 |
|
|
2021
Q2 | $10.1M | Buy |
+115,159
| New | +$10.6M | 0.05% | 514 |
|
|
2021
Q1 | – | Sell |
-125,827
| Closed | -$14.1M | – | 1773 |
|
|
2020
Q4 | $14.1M | Buy |
+125,827
| New | +$13.3M | 0.08% | 351 |
|
|
2020
Q2 | – | Sell |
-76,195
| Closed | -$4.46M | – | 1141 |
|
|
2020
Q1 | $4.46M | Buy |
+76,195
| New | +$4.9M | 0.05% | 433 |
|
|
2018
Q4 | – | Sell |
-5,785
| Closed | -$452K | – | 1415 |
|
|
2018
Q3 | $452K | Buy |
+5,785
| New | +$402K | ﹤0.01% | 1410 |
|
|
2018
Q2 | – | Sell |
-227,549
| Closed | -$20.9M | – | 1787 |
|
|
2018
Q1 | $20.9M | Buy |
227,549
+184,049
| +423% | +$15.9M | 0.09% | 315 |
|
|
2017
Q4 | $3.28M | Sell |
43,500
-46,707
| -52% | -$3.29M | 0.01% | 993 |
|
|
2017
Q3 | $6.29M | Buy |
+90,207
| New | +$4.82M | 0.02% | 640 |
|
Other funds holding BPMC
IA
HNB
Balyasny Asset Management's BPMC Position: Q3 2025 in Review
Balyasny Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 505,957 shares — an estimated $64.9M sold.
Balyasny Asset Management first reported a position in BPMC in Q3 2017 and held it in 15 quarters. The position peaked at $64.9M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Balyasny Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Balyasny Asset Management sold 505,957 Blueprint Medicines shares in Q3 2025, an estimated $64.9M.
- Balyasny Asset Management first reported a position in Blueprint Medicines in Q3 2017 and held it in 15 quarters.
- Balyasny Asset Management's Blueprint Medicines position peaked at $64.9M in Q2 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.